All Stories

  1. Digital technologies in the public-health response to COVID-19
  2. Vaccination against cytomegalovirus
  3. Towards an ultra-rapid smartphone- connected test for infectious diseases
  4. Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection
  5. Cytomegalovirus in pregnancy and the neonate
  6. Complexity of Host Micro-RNA Response to Cytomegalovirus Reactivation After Organ Transplantation
  7. Effects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantation
  8. CD73 Is Dispensable for the Regulation of Inflationary CD8+ T-Cells after Murine Cytomegalovirus Infection and Adenovirus Immunisation
  9. Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients
  10. Restimulating Interest in Cytomegalovirus as a Cofactor for HIV Infection
  11. Taming the Transplantation Troll by Targeting Terminase
  12. Maternal Valacyclovir and Infant Cytomegalovirus Acquisition: A Randomized Controlled Trial among HIV-Infected Women
  13. Development of a novel single tube nested PCR for enhanced detection of cytomegalovirus DNA from dried blood spots
  14. Compartmentalized Cytomegalovirus Replication and Transmission in the Setting of Maternal HIV-1 Infection
  15. Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation
  16. Management of cytomegalovirus infection in haemopoietic stem cell transplantation
  17. Age-Associated Increase of Low-Avidity Cytomegalovirus-Specific CD8+ T Cells That Re-Express CD45RA
  18. Early effectiveness of isolated pectoralis minor tenotomy in selected patients with neurogenic thoracic outlet syndrome
  19. CMV infected or not CMV infected: That is the question
  20. Recognition in a Social Symbiosis: Chemical Phenotypes and Nestmate Recognition Behaviors of Neotropical Parabiotic Ants
  21. Human Herpesvirus Vaccines and Future Directions
  22. The “Silent” Global Burden of Congenital Cytomegalovirus
  23. Supraclavicular decompression for neurogenic thoracic outlet syndrome in adolescent and adult populations
  24. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms
  25. Response to Letter Regarding “Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy”
  26. Acute Cytomegalovirus Infection Is Associated with Increased Frequencies of Activated and Apoptosis-Vulnerable T Cells in HIV-1-Infected Infants
  27. Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation
  28. Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients
  29. Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy
  30. Costochondral calcification, osteophytic degeneration, and occult first rib fractures in patients with venous thoracic outlet syndrome
  31. Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy
  32. Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency
  33. Cytomegalovirus: recent progress in understanding pathogenesis and control
  34. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation
  35. Could a vaccine against immune-evading cytomegalovirus become a reality?
  36. Cytomegalovirus quantification: Where to next in optimising patient management?
  37. Alzheimer disease: are we intervening too late?
  38. Inflammation in common variable immunodeficiency is associated with a distinct CD8+ response to cytomegalovirus
  39. Positional compression of the axillary artery causing upper extremity thrombosis and embolism in the elite overhead throwing athlete
  40. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
  41. Immunotherapy and Vaccination After Transplant: The Present, the Future
  42. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy
  43. Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation
  44. Immunotherapy and Vaccination After Transplant: The Present, the Future
  45. Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture
  46. International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation
  47. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines
  48. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines
  49. Extensive human cytomegalovirus (HCMV) genomic DNA in the renal tubular epithelium early after renal transplantation: Relationship with HCMV DNAemia and long-term graft function
  50. Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4+perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype
  51. Sequence flexibility of the immunodominant HLA A*0201 restricted ppUL83 CD8 T-cell epitope of human cytomegalovirus
  52. The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
  53. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients
  54. Acute cytomegalovirus infection in Kenyan HIV-infected infants
  55. Impact of Genetic Polymorphisms in Cytomegalovirus Glycoprotein B on Outcomes in Solid‐Organ Transplant Recipients with Cytomegalovirus Disease
  56. Combining DNA barcoding and morphological analysis to identify specialist floral parasites (Lepidoptera: Coleophoridae: Momphinae:Mompha)
  57. The detection of cytomegalovirus DNA in maternal plasma is associated with mortality in HIV-1-infected women and their infants
  58. Polyfunctional Cytomegalovirus-Specific CD4+ and pp65 CD8+ T Cells Protect Against High-Level Replication After Liver Transplantation
  59. Genotypic analysis of two hypervariable human cytomegalovirus genes
  60. Impact of HIV on Host‐Virus Interactions during Early Hepatitis C Virus Infection
  61. Functional Impairment of Cytomegalovirus Specific CD8 T Cells Predicts High-Level Replication After Renal Transplantation
  62. Differential Effects of Prednisolone and Azathioprine on the Development of Human Cytomegalovirus Replication Post Liver Transplantation
  63. The ESCRT machinery is not required for human cytomegalovirus envelopment
  64. Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss
  65. Cytomegalovirus in transplantation ? challenging the status quo
  66. Detection of cytomegalovirus in human placental cells by polymerase chain reaction
  67. The T cell response to persistent herpes virus infections in common variable immunodeficiency
  68. Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis
  69. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation
  70. Antiviral treatment after solid organ transplantation
  71. Randomized Trial of a Nurse-Administered, Telephone-Based Disease Management Program for Patients With Heart Failure
  72. Noninfarct vascular dementia and Alzheimer dementia spectrum
  73. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation
  74. Kinetics of Cytomegalovirus Load Decrease in Solid‐Organ Transplant Recipients after Preemptive Therapy with Valganciclovir
  75. Sequence variability of the ?-chemokine UL146 from clinical strains of human cytomegalovirus
  76. Evolution of hepatitis B virus during primary infection in humans: Transient generation of cytotoxic T-cell mutants
  77. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy
  78. Genetic content of wild-type human cytomegalovirus
  79. Susceptibility of porcine cytomegalovirus to antiviral drugs
  80. A Randomized, Controlled Trial Comparing Ganciclovir to Ganciclovir Plus Foscarnet (Each at Half Dose) for Preemptive Therapy of Cytomegalovirus Infection in Transplant Recipients
  81. Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection
  82. The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response
  83. Clinical xenotransplantation
  84. Human Cytomegalovirus Seropositivity Is Associated With Impaired Vascular Function
  85. Two novel spliced genes in human cytomegalovirus
  86. Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hematological patients
  87. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides
  88. Homology between the human cytomegalovirus RL11 gene family and human adenovirus E3 genes
  89. Porcine cytomegalovirus in pigs being bred for xenograft organs: progress towards control
  90. Multimodal feedback: an assessment of performance and mental workload
  91. Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study
  92. Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy
  93. The Prognostic Value of a Single Hepatitis C Virus RNA Load Measurement Taken Early after Human Immunodeficiency Virus Seroconversion
  94. Long-term patterns of hepatitis C virus RNA concentrations in a cohort of HIV seronegative men with bleeding disorders
  95. Guidelines for laboratory monitoring of treatment of persistent virus infections
  96. Cytomegalovirus (CMV) Polymerase Chain Reaction Profiles in Individuals with Advanced Human Immunodeficiency Virus Infection: Relationship to CMV Disease
  97. Human Cytomegalovirus (HCMV) Replication Dynamics in HCMV‐Naive and ‐Experienced Immunocompromised Hosts
  98. Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase
  99. Focus on New Drugs in Development Against Human Cytomegalovirus
  100. Encouraging prospects for immunisation against primary cytomegalovirus infection
  101. Cytomegalovirus (CMV) Resistance to Antivirals
  102. Cytomegalovirus‐Specific Cellular Immune Responses and Viremia in Recipients of Allogeneic Stem Cell Transplants
  103. Nodal Quasiparticles in Stripe Ordered Superconductors
  104. Progress in understanding cytomegalovirus drug resistance
  105. Human Herpesviruses 6 and 7 in Solid Organ Transplant Recipients
  106. Kinetics of Acute Hepatitis B Virus Infection in Humans
  107. CD8+Cytotoxic Lymphocyte Responses against Cytomegalovirus after Liver Transplantation: Correlation with Time from Transplant to Receipt of Tacrolimus
  108. Quantitation of Porcine Cytomegalovirus in Pig Tissues by PCR
  109. Investigation of CMV disease in immunocompromised patients
  110. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations
  111. Quantity of cytomegalovirus DNA in different leukocyte populations during active infection in vivo and the presence of gB and UL18 transcripts
  112. Molecular correlates in AIDS patients following antiretroviral therapy: diversified T-cell receptor repertoires and in vivo control of cytomegalovirus replication
  113. Cytomegalovirus and the Aging Population
  114. Prophylaxis for CMV shouldnot now replace pre-emptive therapy in solid organ transplantation
  115. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients
  116. Relationship between IgM Antibody to Human Cytomegalovirus, Virus Load, Donor and Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for Cytomegalovirus Disease after Liver Transplantation
  117. THE INFLUENCE OF CYTOMEGALOVIRUS VIRAEMIA ON THE OUTCOME OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION12
  118. Histopathological detection of owl's eye inclusions is still specific for cytomegalovirus in the era of human herpesviruses 6 and 7
  119. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
  120. A non-radioisotopic quantitative competitive polymerase chain reaction method: application in measurement of human herpesvirus 7 load
  121. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
  122. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
  123. PROSPECTIVE STUDY OF HUMAN BETAHERPESVIRUSES AFTER RENAL TRANSPLANTATION
  124. TUNING TO THE RIGHT FREQUENCY: CYTOTOXIC T LYMPHOCYTES AND CYTOMEGALOVIRUS
  125. Cytomegalovirus Seropositivity and Human Immunodeficiency Virus Type 1 RNA Levels in Individuals with Hemophilia
  126. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV‐infected patients
  127. Asymptomatic Primary Cytomegalovirus Infection: Virologic and Immunologic Features
  128. Diagnostic approaches to cytomegalovirus infection in bone marrow and organ transplantation
  129. Quantitative Effects of Valacyclovir on the Replication of Cytomegalovirus (CMV) in Persons with Advanced Human Immunodeficiency Virus Disease: Baseline CMV Load Dictates Time to Disease and Survival
  130. Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy
  131. The Dynamics of Human Cytomegalovirus Replication in Vivo
  132. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy
  133. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG)
  134. Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus
  135. Interactions between ?-herpesviruses and human immunodeficiency virus in vivo: Evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6
  136. Viral Dynamics during Active Cytomegalovirus Infection and Pathology
  137. Human complement factor I: its expression by insect cells and its biochemical and structural characterisation
  138. Quantitative differences in the distribution of zidovudine resistance mutations in multiple post-mortem tissues from AIDS patients
  139. Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis
  140. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease
  141. A multiplex PCR assay for the simultaneous detection of human herpesvirus 6 and human herpesvirus 7, with typing of HHV-6 by enzyme cleavage of PCR products
  142. The Effect of Valaciclovir on Cytomegalovirus Viremia and Viruria Detected by Polymerase Chain Reaction in Patients with Advanced Human Immunodeficiency Virus Disease
  143. Development of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistance
  144. HIV‐1 dynamics after transient antiretroviral therapy: Implications for pathogenesis and clinical management
  145. Quantification of CMV viraemia in a case of transfusion-related graft-versus-host disease associated with purine analogue treatment
  146. Diagnosis of primary human herpesvirus 6 and 7 infections in febrile infants by polymerase chain reaction
  147. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease
  148. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation
  149. Prevalence of anti-Vif antibodies in HIV-1 infected individuals assessed using recombinant baculovirus expressedVif protein
  150. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation
  151. Development of a quantitative competitive polymerase chain reaction for human herpesvirus 8
  152. Expression of a human cytomegalovirus gp58 antigenic domain fused to the hepatitis B virus nucleocapsid protein
  153. Detection of human cytomegalovirus polymerase chain reaction products using oligonucleotide probes directly conjugated to alkaline phosphatase
  154. Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases
  155. Production of Plaques in Monolayer Tissue Cultures by Single Particles of an Animal Virus
  156. Transforming Proteins of Human Papillomaviruses
  157. Longitudinal genotype analysis and quantification of hepatitis C virus in haemophilia patients receiving interferon-α therapy
  158. Natural history of untreated cytomegalovirus retinitis
  159. β-Sheet secondary structure of an LDL receptor domain from complement factor I by consensus structure predictions and spectroscopy
  160. Use of the polymerase chain reaction to detect genomes of human immunodeficiency virus and cytomegalovirus in post-mortem tissues
  161. The effect of CMV infection on progression of human immunodeficiency virus disease in a cohort of haemophilic men followed for up to 13 years from seroconversion
  162. Relation between human papillomavirus type 16 and potential for progression of minor-grade cervical disease
  163. HHV-6 in AIDS
  164. Viral burden in HIV infection
  165. Sequence variation within the human immunodeficiency virus V3 loop at seroconversion
  166. The use of baculoviruses as expression vectors
  167. Sequence microheterogeneity in the long control region of clinical isolates of human papillomavirus type 16
  168. Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report
  169. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction
  170. Comparison of cervical cytology and the polymerase chain reaction for HPV 16 to identify women with cervical disease in a general practice population
  171. Eliminating PCR contamination: is UV irradiation the answer?
  172. CYTOMEGALOVIRUS INFECTION AND PROGRESSION TO AIDS
  173. CYTOMEGALOVIRUS INFECTION AND PROGRESSION TOWARDS AIDS IN HAEMOPHILIACS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION
  174. Identification of mutations in the M RNA of a candidate vaccine strain of rift valley fever virus
  175. The development of multiple expression vectors for high level synthesis of eukaryotic proteins: expression of LCMV-N and AcNPV polyhedrin protein by a recombinant baculovirus
  176. Baculovirus Expression Vectors: Choice of Expression Vector
  177. Baculovirus Expression Vectors: Generating a Recombinant Baculovirus
  178. Baculovirus Expression Vectors: Scale-Up and Downstream Processing